{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:24:43Z","timestamp":1785522283919,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Fujian Province Science and Technology Innovation Joint Funding Project","award":["2021Y9028"],"award-info":[{"award-number":["2021Y9028"]}]},{"name":"the Second Affiliated Hospital of Fujian Medical University horizontal scientific research project","award":["HX202201 and HX202202"],"award-info":[{"award-number":["HX202201 and HX202202"]}]},{"name":"the Second Affiliated Hospital of Fujian Medical University Doctoral Research Project","award":["2021GCC03"],"award-info":[{"award-number":["2021GCC03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02326-7","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:35:56Z","timestamp":1779532556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tocilizumab in the treatment of Graves\u2019 orbitopathy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Jianhui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"8","key":"2326_CR1","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1038\/s41433-020-01246-7","volume":"35","author":"B Du","year":"2021","unstructured":"Du B, Wang Y, Yang M, He W. Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases. Eye. 2021;35(8):2294\u2013301.","journal-title":"Eye"},{"issue":"8","key":"2326_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1089\/thy.2015.0031","volume":"25","author":"KA Ponto","year":"2015","unstructured":"Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S, et al. Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid\/Hypothyroid Thyroid-Associated Orbitopathy. Thyroid. 2015;25(8):942\u20138.","journal-title":"Thyroid"},{"issue":"8","key":"2326_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362(8):726\u201338.","journal-title":"N Engl J Med"},{"issue":"4","key":"2326_CR4","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2326_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/105072501753210984","volume":"11","author":"SC Jyonouchi","year":"2001","unstructured":"Jyonouchi SC, Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves\u2019 ophthalmopathy. Thyroid. 2001;11(10):929\u201334.","journal-title":"Thyroid"},{"issue":"3\u20134","key":"2326_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3109\/08830189809042997","volume":"16","author":"T Hirano","year":"1998","unstructured":"Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16(3\u20134):249\u201384.","journal-title":"Int Rev Immunol"},{"key":"2326_CR7","doi-asserted-by":"crossref","unstructured":"Bennedja\u00ef A, Bouheraoua N, Gatfoss\u00e9 M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, et al. Tocilizumab versus Rituximab in patients with moderate to severe steroid-resistant graves\u2019 orbitopathy. Ocul Immunol Inflamm. 2020.","DOI":"10.1080\/09273948.2020.1808688"},{"issue":"4","key":"2326_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10040706","volume":"10","author":"JV P\u00e9rez-Moreiras","year":"2021","unstructured":"P\u00e9rez-Moreiras JV, Varela-Agra M, Prada-S\u00e1nchez MC, Prada-Ramallal G. Steroid-resistant graves\u2019 orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience. J Clin Med. 2021;10(4):1\u201318.","journal-title":"J Clin Med"},{"key":"2326_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, et al. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018;195:181\u201390.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"2326_CR10","first-page":"Cd012984","volume":"11","author":"S Hamed Azzam","year":"2018","unstructured":"Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev. 2018;11(11):Cd012984.","journal-title":"Cochrane Database Syst Rev"},{"key":"2326_CR11","first-page":"n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n160.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"2","key":"2326_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV P\u00e9rez-Moreiras","year":"2014","unstructured":"P\u00e9rez-Moreiras JV, \u00c1lvarez-L\u00f3pez A, G\u00f3mez EC. Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy. Ophthal Plast Reconstr Surg. 2014;30(2):162\u20137.","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"9","key":"2326_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9092816","volume":"9","author":"L S\u00e1nchez-Bilbao","year":"2020","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, L\u00f3pez-V\u00e1zquez \u00c1, Valls-Pascual E, Atienza-Mateo B, et al. Anti-il-6 receptor tocilizumab in refractory graves\u2019 orbitopathy: National multicenter observational study of 48 patients. J Clin Med. 2020;9(9):1\u201315.","journal-title":"J Clin Med"},{"key":"2326_CR14","doi-asserted-by":"crossref","unstructured":"Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab. Clin Endocrinol. 2021.","DOI":"10.1111\/cen.14655"},{"issue":"2","key":"2326_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/IOP.0000000000002027","volume":"38","author":"LD Smith","year":"2022","unstructured":"Smith LD, Moscato EE, Seiff SR. Tocilizumab for the Management of Thyroid-Associated Orbitopathy. Ophthal Plast Reconstr Surg. 2022;38(2):188\u201392.","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"3","key":"2326_CR16","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1097\/IOP.0000000000001346","volume":"35","author":"T Copperman","year":"2019","unstructured":"Copperman T, Idowu OO, Kersten RC, Vagefi MR. Subcutaneous Tocilizumab for Thyroid Eye Disease: Simplified Dosing and Delivery. Ophthal Plast Reconstr Surg. 2019;35(3):e64\u20136.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2326_CR17","doi-asserted-by":"crossref","unstructured":"Canas CA, Bonilla-Abadia F, Vallejo K, Rengifo HM, Gallon MA, Tobon GJ. Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab. Endocr Metab Immune Disord Drug Targets. 2018;18(6):665\u20137.","DOI":"10.2174\/1871530318666180702150243"},{"key":"2326_CR18","doi-asserted-by":"crossref","unstructured":"Dorado Cortez O, Grivet D, Perrillat N, Gain P, Thuret G. Treatment of corticosteroid-resistant Graves\u2019 orbitopathy with tocilizumab: a single-centre prospective study. Orbit (Amsterdam Netherlands). 2022:1\u20137.","DOI":"10.1080\/01676830.2022.2119262"},{"key":"2326_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajoc.2017.07.001","volume":"7","author":"DJ Russell","year":"2017","unstructured":"Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves\u2019 orbitopathy. Am J Ophthalmol case Rep. 2017;7:146\u20138.","journal-title":"Am J Ophthalmol case Rep"},{"issue":"2\u20133","key":"2326_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","volume":"81","author":"J Ceballos-Mac\u00edas Jos\u00e9","year":"2020","unstructured":"Ceballos-Mac\u00edas Jos\u00e9 J, Rivera-Moscoso R, Flores-Real Jorge A, Vargas-S\u00e1nchez J, Ortega-Guti\u00e9rrez G, Madriz-Prado R, et al. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population. Ann Endocrinol. 2020;81(2\u20133):78\u201382.","journal-title":"Ann Endocrinol"},{"issue":"2","key":"2326_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","volume":"28","author":"T Maldiney","year":"2020","unstructured":"Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves\u2019 Ophthalmopathy, a Report of Three Cases. Ocul Immunol Inflamm. 2020;28(2):281\u20134.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"2326_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"2326_CR23","doi-asserted-by":"publisher","first-page":"204201882095833","DOI":"10.1177\/2042018820958335","volume":"11","author":"J L\u00e4ngericht","year":"2020","unstructured":"L\u00e4ngericht J, Kr\u00e4mer I, Kahaly GJ. Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application. Therapeutic Adv Endocrinol metabolism. 2020;11:2042018820958335.","journal-title":"Therapeutic Adv Endocrinol metabolism"},{"issue":"3","key":"2326_CR24","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1210\/clinem\/dgae711","volume":"110","author":"A Sun","year":"2025","unstructured":"Sun A, Wang X, Qu J, Wu Y. The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves\u2019 Ophthalmopathy: A Systematic Review and Single-arm Meta-analysis. J Clin Endocrinol Metab. 2025;110(3):e886\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2326_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s40618-025-02595-4","volume":"48","author":"S Lin","year":"2025","unstructured":"Lin S, Ou X, Cai L, Huang W, Wen J. Efficacy and safety of Tocilizumab for thyroid eye disease: a systemic review and Meta-analysis. J Endocrinol Investig. 2025;48(9):1951\u201365.","journal-title":"J Endocrinol Investig"},{"issue":"10","key":"2326_CR26","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/s41433-025-03845-8","volume":"39","author":"AG Abumohssin","year":"2025","unstructured":"Abumohssin AG, Alshareef RA, Aljohani S, Alqutub A, Alqutub A. Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves\u2019 orbitopathy: a systematic review and meta-analysis. Eye. 2025;39(10):1901\u201332.","journal-title":"Eye"},{"key":"2326_CR27","doi-asserted-by":"publisher","first-page":"1160936","DOI":"10.3389\/fendo.2023.1160936","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Chen J, Lin K, Yu X. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves\u2019ophthalmopathy: a systematic review and meta-analysis. Front Endocrinol. 2023;14:1160936.","journal-title":"Front Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02326-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:13:34Z","timestamp":1785518014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02326-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2326"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02326-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"216"}}